Nyrecancer. Betænkning fra
arbejdsgruppe under Dansk Urologisk Selskab. Klaringsrapport
2002.
Retur
til Indholdsfortegnelse
13.0 Litteratur
1. Clemmensen IH, Storm HH. Kræft i Danmark – en opslagsbog. Kræftens Bekæmpelse 1993.
2. Hellsten S, Berge T, Wehlin L. Unrecognized renal cell carcinoma. Scand J Urol Nephrol 1981; 15: 269-72.
3.
Sweeney JP, Thornhill JA, Grainger R, McDermott
TED, Butler MR. Incidentally detected renal cell carcinoma: pathological
features, survival trends and implications for treatment. Br
J Urol 1996; 78: 351-3.
4.
Rodríguez-Rubio FI, Díez-Caballero F, Martín-Marquina A, Abad JI, Berián
JM. Incidentally detected renal cell carcinoma. Br
J Urol 1996; 78: 29-32.
5. Tosaka A, Ohya K, Yamada K, Ohashi H, Kitahara S, Sekine H et al. Incidence and properties of renal masses and symptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol 1990; 144: 1097-9.
6.
Bretheau D, Lechevallier E, Eghazarian C,
Grisoni V, Coulange C. Prognostic significance of incidental renal cell
carcinoma. Eur Urol 1995; 27: 19-23.
7. Svenska Socialstyrelsen. Medicinsk faktadatabas MARS. State of the art – Njurcancer. Stockholm 2000.
8. Laniel J, Hsia Y. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989; 68: 1-29.
9. Al-Saleem T, Wessner L, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ et al. Malignant tumors of the kidney, brain and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 1998; 83: 2208-16.
10. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N et al. Heriditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999; 155: 517-26.
11.
Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S,
Jacobs SC, Brown RS. Heriditary
renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979; 301: 592-95.
12.
Truong LD, Krishnan B, Cao JT,
Barrios R, Suki WN. Renal
neoplasm inacquired cystic kidney disease. Am
J Kid Dis 1995; 26: 1-12.
13.
Gregoire JB, Torres VE, Holley KE, Farrow GM.
Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant
polycystic kidney disease. Am
J Kid Dis 1987; 9: 27-38.
14. Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol 1994; 4: 1951-6.
15.
Ishikawa I. Uremic acquired renal cystic
disease. Natural history and complications. Nephron
1991; 58: 257-67.
16. Matson MA, Cohen EP. Acquired cystic kidney disease: occurence, prevalence, and renal cancers. Medicine 1990; 69: 217-26.
17. Levine E. Acquired cystic kidney disease. Radiol Clin North Am 1996; 34: 947-64.
18. Bernestein J, Evan AP, Gardner Jr KD. Epithelial hyperplasia in human polycystic kidney disease. It’s role in the pathogenesis and risk of neoplasm. Am J Pathol 1982; 129: 92-101.
19. Gabow PA, Bennett WM. Renal manifestations: complication management and long-term outcome of autosomal dominant polycystic kidney disease. Semin Nephrol 1991; 11: 643-52.
20. Bennington JL, Beckwith JB. Tumors of the kidney, renal pelvis and ureter. Atlas of Tumor Pathology 2nd series. Fascicle # 12. AFIP, Washington DC, 1975.
21. McLaughlin JK, Lindblad P, Mellemgaard A, McCredie M, Mandel JS, Schlehofer B et al. International renal-cell cancer study. I. Tobacco use. Int J Cancer 1995; 60: 194-8.
22.
Doll R. Cancers weakly related to smoking. Br
Med Bull 1996; 52: 35-49.
23. Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. Cancer 1997; 79: 2171-7.
24. Bannasch P, Zuban H. Animal models and renal carcinogenesis. I Eble JN ed. Tumors and tumor-like conditions of the kidney and ureters. New York, Churchill Livingstone, 1990.
25. Mellemgaard A, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark. III. Role of weight, physical activity and reproductive factors. Int J Cancer 1994; 56: 66-71.
26. Kolonel LN. Association of cadmium with renal cancer. Cancer 1976; 37: 1782-87.
27. Kovacs G. Molecular differential pathology of renal tumors. Histopathology 1993; 22 (1): 1-8.
28.
Latbif F, Tory K, Gnavra J, Yao M, Duh FM,
Orcutt ML et al. Identification of the von Hippel-Lindau disease tumor
suppressor gene. Science 1993; 260:
1317-20.
29. Gnavra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
30. Murphy WM, Beckwith JB, Farrow GM. Tumors of the kidney, bladder and related urinary structures. Atlas of Pathology 3rd Series. Fascicle # 11. AFIP, Washington DC, 1994.
31. Mostofi FK, Davis CJ. Histological typing of kidney tumors. WHO, International Histological Classification of tumours, 2nd ed, Springer Verlag 1998.
32.
Lathan B, Cickersin R, Oliva E. Subtypes of
chromophobe renal cell carcinoma. An unstructural and histochemical study of 13
cases. Am J Surg Path 1999;
23: 530-5.
33. Thoenes W, Rumpelt HJ, Storkel S. Classification of renal cell carcinoma/tumors and their relationship to the nephron-collecting tubules system. Klin Wochenschr 1990; 68: 1102-11.
34. Mancilla-Jimenez R, Stanley R, Blath R. Papillary renal cell carcinoma. Cancer 1997; 38: 2469-80.
35. Lager DJ, Huston BJ, Timmermann TG, Bonsibs SM. Papillary renal tumors. Morphologic, cytochemical and genotypic features. Cancer 1985; 76: 669-673.
36. Murad T, Komaiko W, Oyasa R, Bauer K. Multilocular cystic renal cell carcinoma. Am J Pathol 1991; 95: 633-7.
37. Corica F, Iczkowski K, Cheng L, Zincke H, Blute ML, Wendel A et al. Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long term follow-up. J Urol 1999; 161: 408-11.
38. Kanamaru H, Sasaki M, Miwa Y, Akino H, Okada K. Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int 1999; 83: 222-6.
39. Syrjanen K, Hjelt L. Grading of renal adenocarcinoma. Scand J Urol Nephrol 1978; 12:49-55.
40. Lanigan D, Conroy R, Barry-Walsh C, Loftus B, Royston D, Leader M. A comparative analysis of grading systems in renal adenocarcinoma. Histopathology 1994; 24: 473-6.
41.
Tickoo S, Amin M, Zarbo R. Coleoidal iron
staining renal epithelial neoplasms, including renal cell carcinoma. Emphasis on
technique and patterns of staining. Am
J Surg Path 1998; 22: 419-24.
42. Grignon DJ, Abdel-Malak M, Mertens W, Koster J, Keeney M, Sakr W et al. Prognostic significance of cellular proliferation in renal cell carcinoma: A comparison of synthesis-phase fraction and proliferating cell nuclear antigen index. Mod Path 1995; 8: 18-24.
43. Baretton G, Kuhlman B, Kreek R, Löhrs U. Intratumeral heterogenity of nuclear DNA content and proliferation in clear cell type carcinomas of the kidney. Virch Archiv B Cell Pathol 1991; 61: 57-63.
44. Crotty TB, Faroow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 1995; 154: 964-7.
45. Rainwater LM, Farrow GM, Lieber MM. Flow cytometry of renal oncocytoma: common occurrence of deoxyribonucleic acid polyploidy and anenploidy. J Urol 1986; 135: 1168-72.
46. Kovacs G. Molecular cytogenitics of renal cell tumors. Advanced Cancer Research 1993; 62: 89-124.
47. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993; 30: 247-62.
48. Belldegrun A, deKernion JB. Renal tumors. I Campbell’s Urology. 7.ed. W.B. Saunders Company, 1998; vol 3: 2283-2326.
49. Suffrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and serological syndromes of renal adenocarcinoma. Semin Urol 1989; 7: 158-
50.
Boxer RJ, Waisman J, Lieber MM, Mampaso FM,
Skinner DG. Non-metastatic hepatic dysfunction associated with renal carcinoma. J
Urol 1978; 150: 468-71.
51. Fahn HJ, Lee YH, Chen MT, Huang JK et al. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 1991; 145: 248-50.
52. Amendola M, Bree R, Pollack H, Francis IR, Glazu GM, Jafri SZ et al. Small renal cell carcinomas: resolving a diagnostic dilemma. Radiology 1988; 166: 637-41.
53.
Levine E. Renal cell carcinoma: radiological
diagnosis and staging. Semin Roentgenol 1987; 22: 248-59.
54. Bracken RB. Renal carcinoma: clinical aspects and therapy. Semin Roentgenol 1987; 22: 241-7.
55. Pearlman ES, Rosenfield AT, Wexler JS, Glickman MG. CT urography in the evaluation of urinary tract disease. J Comput Assist Tomogr 1996; 20: 620-6.
56.
Einstein D, Hertz B, Weaver R, Obuchowski N,
Zeppo R, Singer A. Evaluation of renal masses detected by excretory urography:
cost-effectiveness of sonography versus CT. AJR
1995; 164: 371-5.
57. Curry N. Small renal masses (lesions smaller than 3 cm): Imaging evaluation and management. Review article. AJR 1995; 164: 355-62.
58. Yamashita Y, Takaheshi M, Watanabe O, Yoshimatzu S, Ucno S, Ishimaru S et al. Small renal cell carcinoma: pathologic and radiologic correlation. Radiology 1992; 184: 493-8.
59. Kier R, Taylor K, Feyock H, Ramos I. Renal masses: characterization with Doppler US. Radiology 1990; 176: 703-7.
60. Bosniak M. The current radiological approach to renal cysts. Radiology 1986; 158: 1-10.
61. Bosniak M. Difficulties in classifying cystic lesions of the kidney. Urol Radiol 1991; 13: 91-3.
62. Bosniak M. Diagnosis and management of patients with complicated cystic lesions of the kidney. AJR 1997; 169: 819-21.
63. Doelle E, Wilson T, Cohan R, Wojno K, Korobkin M. Cystic renal masses: accuracy of the Bosniak Classification System revisited. Association of University Radiologists Annual Meeting, San Diego, Ca, 1995.
64. Aronsen S, Frazier H, Baluck J, Hartman D, Christenson P. Cystic renal masses: usefulness of the Bosniak classification. Urol Radiol 1991; 13: 83-90.
65. Bosniak M. The small (3.0 cm or less) renal parenchymal tumor: detection, diagnosis and controversies. Radiology 1991; 179: 307-17.
66. Silvermann SG, Lee BY, Seltzer SE, Bloom DA, Corless CL, Adams DF. Small (3 cm or less) renal masses: correlation of spiral CT features and pathologic findings. AJR 1994; 163: 597-605.
67. Levine E, Huntrakoon M, Wetzel L. Small renal neoplasms: clinical, pathological, and imaging features. AJR 1989; 153: 69-73.
68. Mammadeh MY, Thomas K, Philp T, Singh M. Renal cell carcinoma containing fat mimicking angiomyolipoma: demonstration with CT scan and histopathology. Eur Radiol 1998; 8: 228-9.
69.
Davidson A, Hayes W, Hartman D, McCarthy W,
Davis C. Renal oncocytoma and carcinoma: failure of differentation with CT. Radiology
1993; 186:693-6.
70. Xipell J. The incidence of benign renal nodules. J Urol 1993; 186: 693-6.
71. Birnbaum B, Bosniak M, Megibow A, Lubat E, Gordon R. Observations on the growth of renal neoplasms. Radiology 1990; 176: 695-701.
72. Peterson R. Urologic Pathology. Philadelphia: Lippincott, 1986: 85-7.
73. Smith S, Bosniak M, Megibow A, Hulnick DH, Horii SC, Raghavendra BN. Renal cell carcinoma: earlier discovery and increased detection. Radiology 1989; 170: 699-703.
74. Licht M, Novick A. Nephron sparing surgery for renal cell carcinoma. J Urol 1993; 149: 1-7.
75. Black W, Ling A. Is earlier diagnosis better? The misleading effect of lead time and length biases. AJR 1990; 155: 625-30.
76. Eilenberg S, Lee J, Brown J, Mirowitz S, Tartar V. Renal masses: evaluation with gradient-echo Gd-DTPA-enhanced dynamic MR imaging. Radiology 1990; 176: 333-8.
77. Rofsky NM, Bosniak MA. MR imaging in the evaluation of small (< 3.0 cm) renal masses. MRI clinics of NA, volume 5, number 1, 1997.
78. De Fossez S, Yoder I, Papanicolau N, Rosen B, McGovern F. Nonspecific magnetic resonance appearance of renal oncocytomas: Report of 3 cases and review of the literature. J Urol 1991; 147: 552-4.
79. McClennan BL, Deyoe LA. The imaging evaluation of renal cell carcinoma: diagnosis and staging. Rad Clin North Am 1994; 32: 55-69.
80. Choyke PL, Walther MM, Wagner JR, Rayford W, Lyne JC, Linehan WM. Renal cancer: preoperative evaluation with dual-phase three-dimensional MR angiography. Radiology 1997; 205: 767-71.
81.
Amis E, Cronan J, Pfister R. Needle puncture of
cystic renal masses: a survey of the Society of Uroradiology. AJR
1987; 148: 297-9.
82.
Fein AB, Lee JKT,
Balfe DM. Diagnosis and staging of renal cell
carcinoma; a comparison of MRI and CT. AJR 1987; 148: 749-53.
83.
Johnson CK, Dunnick NR, Cohan RH, Illescas FF.
Renal adenocarcinoma: CT staging of 100 tumors. AJR
1987; 148: 59-63.
84. Constantinides C, Recker F, Bruehlmann W, von Schulthess G, Goebel N, Zollikofer C et al. Accuracy of MRI compared to CT and selective angiography in staging renal cell carcinoma. Urol Int 1991; 47: 181-5.
85. Amendola MA, King CR, Pollack HM, Gefter W, Kressel HY, Wein AJ. Staging renal carcinoma using MRI at 1,5 T. Cancer 1990; 66: 40-4.
86. Hatcher PA, Poulson DT, Anderson EE. Accuracy in staging renal cell carcinoma involving vena cava. Urology 1992; 39: 27-30.
87. Cosgrove D, Meire H, Derobury K ed. Abdominal and General Ultrasound. Churchill Livingston. 1993; 374 og 493.
88.
Studer UE, Scherz S,
Scheidegger J, Kraft R, Sonntag R, Ackermann D et al. Enlargement
of regional lymph nodes in renal carcinoma is often not due to metastases. J
Urol 1990; 144: 243-5.
89.
Miles KA, London NJM, Lavelle JM, Messios N, Smart JG. CT staging of
renal carcinoma: a prospective comparison of three dynamic computed tomography
techniques. Eur J Rad 1991; 13: 37-42.
90.
Krestin GP, Gross-Fengels W, Marincek B. The use of magnetic resonance
imaging for diagnosis and staging of renal cell carcinoma. Radiology 1992; 32:
121-5.
91.
Fritsche PJ, Millar C. Multimodality approach to staging renal cell
carcinoma. Urol Radiol 1992; 14: 3-7.
92.
Mogensen P, Rossing N, Giese J. Glomerular
filtration rate measurement and 131I-Hippuran renography before
unilateral nephrectomy. Scand J Urol Nephrol 1972; 6: 228-31.
93.
Robson CJ, Churchill BM, Anderson W. The
results of radical nephrectomy for renal carcinoma. J Urol 1969; 101: 297-301.
94.
Leibovitch I, Raviv G, Mor Y, Nativ O,
Goldwasser B. Reconsidering the necessity of ipsilateral adrenalectomy during
radical nephrectomy for renal cell carcinoma. Urology 1995; 46: 319-20.
95.
Shalev M, Cipolla B, Guille F, Staerman F,
Lobel B. Is ipsilateral adrenalectomy a necessary component of radical
nephrectomy? J Urol 1995; 153: 1415-7.
96.
Paul R,
Mordhorst J, Busch R, Leyh H, Hartung R. Adrenal sparing surgery during radical
nephrectomy in patients with renal cell cancer: a new algorithm. J
Urol 2001; 166: 59-62.
97.
Hvidt V. Nyretumorer. I: Hald T, Stadil F. Kirurgisk kompendium. København;
Arnold Busk, 1996: 1418-33.
98.
Hyman MJ, Katz J, Russo P. Impact of regional lymph node dissection in
the treatment of renal cell carcinoma. 95th Annual Meeting of the
American Association of Urology 2000, Atlanta GA, USA.
99.
Licht MR, Novick AC. Nephron sparing surgery
for renal cell carcinoma. J Urol 1993; 149: 1-7.
100.
Licht MR, Novick AC, Goormastic M. Nephron
sparing surgery in incidental versus suspected renal cell carcinoma. J Urol
1994; 152: 39-42.
101.
Novick AC. Nephron sparing surgery for renal
cell carcinoma. Br J Urol 1998; 82:
321-4.
102.
Morgan WR, Zincke H. Progression and survival
after renal-conserving surgery for renal cell carcinoma: experience in 104
patients and extended follow-up. J Urol 1990; 144: 852-7.
103.
Moll V, Becht E, Ziegler M. Kidney preserving
surgery in renal cell tumors: indications, techniques and results in 152
patients. J Urol 1993; 150: 319-23.
104.
Fergany AF, Hafez KS, Novick AC. Long-term
results of nephron sparing surgery for localized renal cell carcinoma: 10-years
followup. J Urol 2000; 163: 442-5.
105.
Yip SK, Cheng WS, Tan BS, Li MK. Partial
nephrectomy for renal tumours: The Singapore General Hospital experience. JR
Coll Surg Edin 1999; 44: 156-60.
106.
Duque JL, Loughlin KR, O’Leary MP, Kumar S,
Richie JP. Partial nephrectomy: alternative treatment of selected patients with
renal cell cancer. Urology 1998; 52: 584-90.
107.
Kletscher BA, Lauvetz RW, Segura JW.
Nephron-sparing laparoscopic surgery: techniques to control the renal pedicle
and manage parenchymal bleeding. J Endourol 1995; 9 (1): 23-30.
108.
Ono Y, Katoh N, Kinukawat T,
Matsuura O, Oshima S. Laparoscopic radical nephrectomy: the Nagoya experience. J Urol 1997; 158: 719-23.
109.
Dunn MD, Portis
AJ, Shalhav AL, Elbahnasy AM, Heidorn C. Laparoscopic versus open radical
nephrectomy: a 9-year experience. J Urol 2000; 164: 1153-9.
110.
Meraney AM, Gill IS,
Savage SJ, Schweizer DK, Kaouk JH, Sung GT et al. Oncologic
adequacy of laparoscopic radical nephrectomy. 95th Annual Meeting of
the American Association of Urology 2000, Atlanta GA, USA.
111.
Ljunberg B, Stenling R, Osterdahl B, Farrelly
E, Aberg T, Roos G. Vein invasion in renal cell carcinoma: impact on metastatic
behaviour and survival. J Urol 1995; 154 (5): 1681-4.
112.
Hatcher PA, Anderson EE, Paulson DF, Carson CC,
Robertson JE. Surgical management and prognosis of renal cell carcinoma invading
the vena cava. J Urol 1991; 145 (1): 20-3.
113.
Pagano F, Dal Bianco M, Artibani W, Pappagello
G, Prayer Galetti T. Renal cell carcinoma with extension into the inferior vena
cava: problems in diagnosis, staging and treatment. Eur Urol 1992; 22 (3):
200-3.
114.
Golimbu M, Joshi P, Sperber A, Tessler A,
Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors.
Urology 1986; 27 (4): 291-301.
115.
Sanchez de la Muela P, Zudadaire JJ, Robles JE,
Rosell D, Aguera L, DeCastro F et al. Renal cell carcinoma: vena caval invasion
and prognostic factors. Eur Urol 1991; 19 (4): 284-90.
116.
Giuliani L, Giberti C, Martorana G, Rovida S.
Radical extensive surgery for renal cell carcinoma: Long-term results and
prognostic factors. J Urol 1990; 143:
468-74.
117.
Van Poppel H, Vandendriessche
H, Boel K, Mertens V, Goethuys H, Haustermans K et al. Microscopic
vascular invasion is the most relevant prognosticator after radical nephrectomy
for clinically nonmetastatic renal cell carcinoma. J Urol 1997; 158: 45-9.
118.
Cherrie RJ, Goldman DG, Lindner A, deKernion
JB. Prognostic implications of vena caval extension of renal cell carcinoma. J
Urol 1982; 128: 910-2.
119.
Almgard LE, Fernstrom I, Haverling M,
Ljungqvist A. Treatment of renal adenocarcinoma by embolic occlusion of the
renal circulation. Br J Urol 1973; 45:
474-9.
120.
Bakal CW, Cynamon J, Lakritz PS, Sprayregen S.
Value of preoperative renal artery embolization in reducing blood transfusion
requirements during nephrectomy for renal cell carcinoma. J Vasc Intervent Rad
1993; 4: 727-31.
121.
Craven WM, Redmond PL, Kumpe DA, Durham JD,
Wetterlaufer JN. Planned delayed nephrectomy after ethanol embolization for
renal carcinoma. J Urol 1991; 146: 704-8.
122.
Lanigan D, Juriaans E, Hammonds JC, Wells IP,
Choa RG. The current status of embolization in renal cell carcinoma – a survey
of local and national practice. Clin Rad 1992; 46: 176-8.
123.
Hom D, Eiley D,
Lumerman JH, Siegel DN, Goldfischer ER, Smith AD. Complete
renal embolization as an alternative to nephrectomy. J Urol 1999; 161: 24-7.
124.
McCaffrey JA, Motzer RJ. What is the role of
nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996;
23: 19-20.
125.
Belldegrun A, Schwarts O, Figlin R. Expanding
the indication for surgery and adjuvant interleukin-2 based immunotherapy in
patients with advanced renal cell carcinoma. Cancer J Sci Am 6 2000; Suppl 1:
88-92.
126.
Rackley R, Novick A, Klein E, Bukowski R,
McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality
treatment of metastatic renal cell carcinoma. J Urol 1994; 152: 1399-1403.
127.
Benneth RT, Lerner SE, Taub HC, Dutcher JP,
Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol
1995; 154: 32-4.
128.
Walther MM, Yang JC, Pass HI, Linehan WM,
Rosenberg SA. Cytoreductive surgery before high-dose interleukin-2 based therapy
in patients with metastatic renal cell carcinoma. J Urol 1997; 158: 1675-8.
129.
Sella A, Swanson DA, Ro JY, Putnam JB Jr, Amato
RJ, Markowitz AB et al. Surgery
following response to interferon-alpha based therapy for residual renal cell
carcinoma. J Urol 1993; 149:
19-22.
130.
Motzer RJ, Bander NH,
Nanus DM. Renal cell carcinoma. N
Engl J Med 1996; 335: 865-75.
131.
Motzer RJ, Russo P,
Nanus DM, Berg WJ. Renal cell carcinoma. Curr Probl
Cancer 1997; 21: 189-223.
132. Kavolius JP, Mastorakos DP, Pavolvich C, Russo P, Burt ME, Brady MS. Resections of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-6.
133. Progrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: Resection of solitary and multiple metastases. Ann Thorac Surg 1992; 54: 33-8.
134. Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single-dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998; 47: 223-40.
135. Harris DT. Hormonal therapy and chemotherapy of RCC. Semin Oncol 1983; 10: 422-30.
136. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177-86.
137. Minasian L, Motzer R, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11: 1368-75.
138. Fosså SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27: 187-93.
139. Fosså SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Ann Oncol 1992; 3: 301-5.
140. Neidhart JA, Anderson SA, Harris JE, Rinehart JJ, Laszlo J, Dexus FH et al. Vinblastine fails to improve response of renal cancer to interferon alfa-N1: High response rate in patients with pulmonary metatstases. J Clin Oncol 1991; 9: 832-7.
141. Von der Maase H, Geertsen PF, Thatcher N, Jasmin C, Mercatello A, Fossa SD et al. Recombinant interleukin-2 in metastatic renal cell carcinoma – a European multicentre phase II study. Eur Cancer 1991; 27: 1583-9.
142. Geertsen PF, Hermann GG, von der Maase H, Steven K. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single center phase II study. J Clin Oncol 1992; 10: 753-9.
143. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 1997; 80: 1198-1220.
144. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am 1997; 3: 70-2.
145. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27: 194-203.
146. Bukowsky RM. Cytokine cimbinations: Therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000; 27: 204-12.
147.
Negrier S, Escudier B, Lasset C, Douillard JY,
Savary J, Chevreau C et al. Recombinant human interleukin-2, recombinant
interferon alfa-2a, or both in metastatic renal cell carcinoma. N
Engl J Med 1996; 338: 1272-9.
148. Henriksson R, Nilsson S, Colleen S, Wersall P, Helsing M, Zimmerman R et al. Survival in renal cell carcinoma – a randomized evaluation of tamoxifen vs interleukin-2, alfa-interferon (leukocyte) and tamoxifen. Br J Cancer 1998; 77: 1311-7.
149. Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alfa and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 1993; 29A: 56-8.
150. Hoffman DMJ, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol 2000; 27: 221-33.
151. Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Medicine 2000; 6: 332-6.
152.
Childs R, Chernoff A, Contentin N, Bahceci E,
Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after
nonmyeloablative allogenic peripheral-blood stem-cell transplantation. N
Engl J Med 2000; 343: 750-8.
153.
Slavin S. Cancer immunotherapy with
alloreactive lymphocytes. N Engl J Med
2000; 343: 802-3.
154. Ljungberg B, Alamdari FI, Holmberg G, Granfors T, Duchek M. Radical nephrectomy is still preferable in the treatment of localized renal cell carcinoma. Eur Urol 1998; 33: 79-85.
155. Zincke H, Lau W, Blute M. Stage T1 renal cell carcinoma: significance of tumor size as independent predictor of outcome after radical nephrectomy. 95th Annual Meeting of the American Association of Urology 2000, Atlanta GA, USA.
156. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001; 166: 453-6.
157.
Sobin LH, Wittekind C. TNM classification of
malignant tumors. International Union Against Cancer (UICC). 5th ed.
New York: Wiley-Liss; 1997: 180-2.
158. Javidan J, Stricker HJ, Tamboli P, Amin MB, Peabody JO, Deshpande A et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999; 162: 1277-81.
159. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995; 154: 28-31.
160. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159 (4): 1163-7.
161.
Ljungberg B, Alamdari FI, Rasmuson T, Roos G.
Follow-up guidelines for nonmetastatic renal cell carcinoma based on the
occurrence of metastases after radical nephrectomy. BJU
Int 1999; 84 (4): 405-11.
Dansk Urologisk Selskab 2002